Capstone Investment Advisors
GNCA

Capstone Investment Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History

Capstone Investment Advisors’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-27,818
Closed -$67K – 2036
2020
Q4 		$67K Buy
+27,818
New +$63.4K ﹤0.01% 1602

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Capstone Investment Advisors's GNCA Position: Q1 2021 in Review

Capstone Investment Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q1 2021, closing a stake of 27,818 shares — an estimated $67K sold.

Capstone Investment Advisors first reported a position in GNCA in Q4 2020 and held it in 1 quarter. The position peaked at $67K in Q4 2020. 42 funds tracked by Wall St. Rank hold GNCA as of Q1 2021.

  • Capstone Investment Advisors reported no remaining Genocea Biosciences, Inc. position as of Q1 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 27,818 Genocea Biosciences, Inc. shares in Q1 2021, an estimated $67K.
  • Capstone Investment Advisors first reported a position in Genocea Biosciences, Inc. in Q4 2020 and held it in 1 quarter.
  • Capstone Investment Advisors's Genocea Biosciences, Inc. position peaked at $67K in Q4 2020.
  • 42 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q1 2021.

Based on Capstone Investment Advisors's 13F filing for Q1 2021, filed 17 May 2021.